

INSIGHTS OF THE FUTURE


now

We're coming for you, cancer.



FoundationOne® Analysis Platform + AVENIO Connect Software

Secondary analysis and data management software



Thoroughly validated variant calling knowledgebase

- Built on insights from Foundation Medicine's experience in profiling over 1.3 million+ samples.¹
- Continuously evolving based on evidence compiled from databases such as COSMIC, dbSNP, gnomAD, 1000 Genomes.²



Cloud-based computing for efficient analysis

- Converts uploaded BCL files to FASTQ, demultiplexes reads, and downsamples.*
- Enables regular updates to minimize downtime and manual intervention.
- Allows for seamless hardware integration.



Broad genomic coverage

- Identifies all four types of genomic variants including Single Nucleotide Variants, Insertions and Deletions, Copy Number Alterations, and Rearrangements.^{3,4}
- Calculates genomic signatures such as TMB, MSI, gLOH, and newly added HRD signature (HRDsig).³⁻⁵
- Variant calls in all captured regions, not limited to pre-defined set of hotspots.



Confidence in high-quality results

- 14+ QC metrics, including median coverage and potential contamination, used to assess data quality.⁴
- Enables users to filter and annotate genomic data for criticality, relevance and biological significance.³

AVENIO Tumor Tissue CGP Kit V2 is For Research Use Only. Not for use in diagnostic procedures.

TMB, tumor mutational burden. MSI, Microsatellite instability. gLOH, genomic loss of heterozygosity. HRD, homologous recombination deficiency. QC, quality control.
* BCL files are the raw data files generated by the Illumina sequencers. FASTQ format is a text-based format for storing both a biological sequence and its corresponding quality scores.

AVENIO Tumor Tissue CGP Kit V2
Powered by **FOUNDATION MEDICINE**

INSIGHTS OF THE FUTURE now

We're coming for you, cancer.

Gain access to clear information and results

Web application for download of analysis output files

- VCF (SNVs and InDels)
- JSON (CNAs, REs, TMB, MSI, gLOH and HRDsig)
- CSV (QC metrics & variants combined)
- BAM (alignment file)

The screenshot displays the 'Orders' page for sample ID FMla20_0092. The interface includes a navigation bar with 'Details', 'Workflow', 'Results', and 'QC metrics'. A 'Completed Readout' card shows the primer plate type as 'Plate B', primer well position as 'C1', and start/end dates as '21-Nov-2020 04:46 PM PST'. Below this is a table of sample details with columns for Sample ID, Test name, Primer plate type, Primer well position, Status, and Comments. The table lists eight samples, all with a 'Completed' status. A right-hand sidebar shows the analysis status as 'Completed', start/end dates as '03-Aug-2021 04:00 PM PST' and '03-Aug-2021 10:33 PM PST', and analysis version '0.9'. It also provides a download link for 'All results (ZIP)' and a link to the 'FoundationOne_Analysis_Platform'.

Sample ID	Test name	Primer plate type	Primer well position	Status	Comments
FMla20_0091	AVENIO Tumor Tissue CG...	Plate B	B1	Completed	Add a comment
FMla20_0097	AVENIO Tumor Tissue CG...	Plate B	A2	Completed	Add a comment
FMla20_0095	AVENIO Tumor Tissue CG...	Plate B	F1	Completed	Add a comment
FMla20_0096	AVENIO Tumor Tissue CG...	Plate B	G1	Completed	Add a comment
FMla20_0092	AVENIO Tumor Tissue CG...	Plate B	C1	Completed	Add a comment
FMla20_0093	AVENIO Tumor Tissue CG...	Plate B	D1	Completed	Add a comment
FMla20_0094	AVENIO Tumor Tissue CG...	Plate B	E1	Completed	Add a comment
FMla20_0090	AVENIO Tumor Tissue CG...	Plate B	A1	Completed	Add a comment

1. Foundation Medicine Biopharma services. Available at: <https://www.foundationmedicine.com/info/biopharma-overview> (Accessed July 2024).

2. Foundation Medicine® About Us. Available at: <https://www.foundationmedicine.com/info/detail/our-story> (Accessed July 2024).

3. Data on file.

4. AVENIO Tumor Tissue CGP Kit V2 Instructions for Use June 2024.

5. Chen KT et al. A Novel HRD Signature Is Predictive of FOLFIRINOX Benefit in Metastatic Pancreatic Cancer. *Oncologist*. 2023 Aug 3;28(8):691-698. doi: 10.1093/oncolo/oyad178.

AVENIO Tumor Tissue CGP Kit V2 is For Research Use Only. Not for use in diagnostic procedures.

SNV=Single Nucleotide Variant, InDel=Insertion and Deletion, CNA=Copy Number Alteration, TMB=Tumor Mutational Burden, MSI=Microsatellite Instability, gLOH=genomic Loss of Heterozygosity, HRDsig=Homologous Recombination Deficiency Signature, QC=Quality Control

© 2024 F. Hoffmann-La Roche Ltd.

AVENIO is a registered trademark of Roche. FOUNDATIONONE is a registered trademark of Foundation Medicine, Inc. All other product names and trademarks are the property of their respective owners.

For more information on FoundationOne® Analysis Platform and AVENIO Connect Software please reach out to your local Roche Sequencing representative.

MC-US-15630 08/2024

AVENIO Tumor Tissue CGP Kit V2
Powered by FOUNDATION MEDICINE